Sugi Predict

Sugi Predict / Compounds / SCHEMBL2695885

SCHEMBL2695885

SCHEMBL2695885

OC(c1ccc2ncccc2c1)c1nnc2ccc(-c3ccccc3)nn12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 20/20 1.00
▸ PDE3B Q13370 4/20 0.60
▸ PDE3A Q14432 4/20 0.60
▸ PDE1A P54750 3/20 0.60
▸ PDE4C Q08493 3/20 0.60
▸ PDE4D Q08499 3/20 0.60
▸ PDE1C Q14123 3/20 0.60
▸ PDE11A Q9HCR9 3/20 0.60
▸ PDE10A Q9Y233 3/20 0.60
▸ PDE2A O00408 1/20 0.59
▸ CHRM2 P08172 1/20 0.59
▸ PDE4A P27815 1/20 0.59
▸ PDE4B Q07343 1/20 0.59
▸ ABL1 P00519 1/20 0.46
▸ NQO2 P16083 1/20 0.46
▸ MAPK8 P45983 1/20 0.46
▸ MAPK10 P53779 1/20 0.46
▸ DYRK1A Q13627 1/20 0.46
▸ MAP3K19 Q56UN5 1/20 0.46
▸ PIP4K2C Q8TBX8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2699090 1.00 MET (1.00) METPDE3BPDE3APDE1APDE4C
SCHEMBL2695879 1.00 MET (1.00) METPDE3BPDE3APDE1APDE4C
SCHEMBL2699300 0.87 MET (1.00) METPDE3BPDE3APDE1APDE4C
SCHEMBL9910377 0.87 MET (0.77) METPDE3BPDE3APDE1APDE4C
SCHEMBL2696561 0.87 MET (1.00) METPDE3BPDE3APDE1APDE4C
SCHEMBL9910375 0.87 MET (0.77) METPDE3BPDE3APDE1APDE4C
SCHEMBL2697942 0.87 MET (1.00) METPDE3BPDE3APDE1APDE4C
SCHEMBL12049407 0.78 MET (0.67) METPDE3BPDE3APDE1APDE4C
SCHEMBL12049406 0.78 MET (0.65) METPDE3BPDE3APDE1APDE4C
SCHEMBL14199032 0.77 MET (0.64) METPDE3BPDE3APDE1APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 — — EP disclosed
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 — — EP disclosed
EP-2081931-B1 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor AMGEN INC (US) 2016-08-31 — — EP disclosed
EP-2081931-B1 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor AMGEN INC (US) 2016-08-31 — — EP disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 — — US disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 — — US disclosed
US-9066954-B2 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2015-06-30 — — US disclosed
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-11-14 — — US disclosed
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-11-14 — — US disclosed
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-11-14 — — US disclosed
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 — — US disclosed
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 — — US disclosed
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 — — US disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 — — US disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
WO-2008008539-A2 FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR AMGEN INC. (US) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318436-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET MET 3/4885PDE3B 1730/4885PDE3A 1765/4885
US-20090124612-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET MET 3/4885PDE3B 1730/4885PDE3A 1765/4885
US-20130303529-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET MET 3/4885PDE3B 1730/4885PDE3A 1765/4885
US-20090124609-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET MET 3/4885PDE3B 1730/4885PDE3A 1765/4885
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET MET 3/4885PDE3B 1730/4885PDE3A 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.